Stifel Nicolaus Has Lowered Expectations for Inventiva (NASDAQ:IVA) Stock Price

Posted by Irma Garcia on Nov 22nd, 2024

Inventiva (NASDAQ:IVA – Get Free Report) had its price target cut by research analysts at Stifel Nicolaus from $20.00 to $17.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other brokerages have also recently issued reports on IVA. UBS Group initiated coverage on shares of Inventiva in a report on Tuesday, November 12th. They issued a “neutral” rating and a $3.00 target price on the stock. HC Wainwright dropped their target price on Inventiva from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, October 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $13.25.

View Our Latest Report on Inventiva

Inventiva Price Performance

Shares of NASDAQ IVA traded down $0.08 during trading on Friday, hitting $2.66. 14,169 shares of the company traded hands, compared to its average volume of 76,257. Inventiva has a fifty-two week low of $1.53 and a fifty-two week high of $4.75. The business’s fifty day moving average is $2.37 and its 200 day moving average is $2.66.

Institutional Investors Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC acquired a new stake in Inventiva S.A. (NASDAQ:IVA – Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

(Get Free Report)

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.